1. Home
  2. SBGI vs COLL Comparison

SBGI vs COLL Comparison

Compare SBGI & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sinclair Inc.

SBGI

Sinclair Inc.

HOLD

Current Price

$15.21

Market Cap

1.1B

Sector

Industrials

ML Signal

HOLD

Logo Collegium Pharmaceutical Inc.

COLL

Collegium Pharmaceutical Inc.

HOLD

Current Price

$49.42

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SBGI
COLL
Founded
1986
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Broadcasting
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.5B
IPO Year
1995
2015

Fundamental Metrics

Financial Performance
Metric
SBGI
COLL
Price
$15.21
$49.42
Analyst Decision
Buy
Strong Buy
Analyst Count
5
6
Target Price
$21.00
$47.50
AVG Volume (30 Days)
400.8K
488.1K
Earning Date
11-05-2025
11-06-2025
Dividend Yield
6.55%
N/A
EPS Growth
N/A
N/A
EPS
N/A
1.63
Revenue
$3,337,000,000.00
$757,067,000.00
Revenue This Year
N/A
$26.35
Revenue Next Year
$10.36
$3.67
P/E Ratio
N/A
$30.66
Revenue Growth
N/A
26.34
52 Week Low
$11.89
$23.23
52 Week High
$17.88
$50.01

Technical Indicators

Market Signals
Indicator
SBGI
COLL
Relative Strength Index (RSI) 46.88 67.46
Support Level $15.09 $48.50
Resistance Level $15.51 $49.92
Average True Range (ATR) 0.62 1.28
MACD -0.12 -0.22
Stochastic Oscillator 20.95 72.25

Price Performance

Historical Comparison
SBGI
COLL

About SBGI Sinclair Inc.

Sinclair Inc. is the owner-operator of the second largest portfolio of television stations in the United States, with 185 full power stations in 86 markets, covering 40% of US households. Of the firm's roughly 600 channels, 150 are affiliated with the four national broadcasters—Fox, ABC, CBS, and NBC—with over 80 other channels aligned with The CW (Nexstar) and MyNetworkTV (Fox). Sinclair owns the Tennis Channel and stakes in Marquee Sports Network and YES Network, providing their premium sports content to pay-TV distributors.

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

Share on Social Networks: